GenomeKey

Employee Spotlight: As part of a new series, let us introduce you to our Head of Engineering, Matt Davies. Matt is based at our research and development facility in Bristol, UK and has been part of the GenomeKey team since February. Matt says, “GenomeKey has already developed software to speed the treatment of sepsis by identifying bacterial strains in blood, and any antimicrobial resistance, via Whole Genome Sequencing. They've developed a biochemical process to enable the WGS, at sensitivities equivalent to the gold standard, in a timeframe that allows more effective treatment. I'm leading the engineering team that is automating that biochemical process and developing an instrument that can be placed into any hospital or clinical microbiology laboratory to speed up the time from sample to targeted, more effective, treatment and to reduce the workload on clinical scientists while still enabling them to process more samples more rapidly.   GenomeKey's focus on finding a solution to a problem that is affecting more and more people around the world, and becoming harder to treat as antibiotic resistance increases, initially attracted me, but the great leadership team, the truly collaborative attitude of the people here and the caring, supportive, but still fast paced and intellectually demanding environment that has been created, keep me excited to start work every day.”

Today, the United Nations is holding a General Assembly High-Level Meeting on antimicrobial resistance 2024 today to highlight the urgent threat posed by AMR. This meeting is pivotal in raising global awareness and galvanizing action to combat this silent pandemic. We at GenomeKey are working towards improvements to diagnostics by providing a rapid bacterial species and AMR profiling IVD for bacterial blood stream infections. Our diagnostic will help curb the spread of AMR, ensuring patients are put onto the right treatment within just 7 hours, saving patients lives. Watch the live stream here

Join Michael Roberts, our CEO, as he discusses GenomeKey's journey and reveals key strategies for scaling a biotechnology startup. Don't miss his talk at the Panel Discussion hosted by SETsquared Bristol on October 9th!

We are excited to announce that GenomeKey are Corporate Supporters of Science Creates Outreach! GenomeKey is building a world where nobody dies from a treatable infection by transforming diagnostics with their next-generation IVD device, which maps the right antibiotic to the right patient, in just hours. The specialist team delivers a variety of inspiring workshops in The Learning Lab to educate the next generation of scientists, so we are thrilled to have them in our network of supporters and to be working with them to make a difference. If your company would also like to make a big impact in the community, be celebrated for your social commitments and enjoy an exclusive package of resources and support from us in return, please click here to get in touch: https://lnkd.in/eTh4Kwue #TheLearningLab #STEM #outreach #inspiringthenextgeneration

We're thrilled that GenomeKey has been awarded $11.4M to transform sepsis diagnosis and treatment. Read more👉https://bit.ly/4dqjMOa The major grant was from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to build a functioning, automated prototype of their desktop diagnostic device.👏👏 The Bristol-based company joined our incubation programme in 2020 with a vision to build an in vitro diagnostic device that would completely transform the way we diagnose and treat sepsis and other bacterial infections. GenomeKey’s next-generation device will be able to detect and identify bacteria directly from patient blood, delivering a full antimicrobial resistance (AMR) profile in just hours. Michael Roberts, GenomeKey CEO, said: “We have a vision of the world where nobody dies from a treatable infection. Right now, the gold standard test takes too long and has a high false-negative rate. We’re giving clinicians the information they need, much faster, so they can deliver rapid diagnostics testing and precision medicine for a more targeted treatment. #Healthtech #Biotech #Startups #Founders #Incubator #Accelerator

CARB-X is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. They awarded GenomeKey US$11.4 million to continue their important work developing a next-generation in vitro diagnostic device that’s set to become the new standard for bacterial identification. Find out more here: https://lnkd.in/dxmw9Z4b

This major grant of US$11.4 million was awarded by global non-profit CARB-X. The CARB-X portfolio is the world’s most diverse antibacterial R&D portfolio. Erin Duffy, Ph.D., R&D Chief of CARB-X says, “It is imperative to direct treatment quickly with the right antibiotic treatment, and GenomeKey’s technology has the potential to help practitioners direct the appropriate treatment by delivering a phenotypic antibiotic sensitivity prediction based on rapid whole genome sequencing direct from blood.” Find out more here: https://lnkd.in/dxmw9Z4b

GenomeKey will partner with Oxford Nanopore Technologies to develop an automated, bench-top device designed to rapidly detect, identify and evaluate antimicrobial susceptibility in as little as hours rather than days. Read more in our press release here: https://lnkd.in/e3Rsyf92 #AMR #Oxfordnanoporetechnologies #Genomekey

GenomeKey will partner with the Oxford-based company to develop an automated, bench-top prototype to produce “real world” data direct from blood, giving lab clinicians the power to rapidly detect, identify and evaluate antimicrobial susceptibility in as little as hours rather than days. Read the press release to find out more about this partnership and what it means: https://lnkd.in/efK3E5bS

Join Dr Michael Roberts and Dr Dan Rogerson today to talk about the future of whole genome sequencing, sepsis diagnosis and the war on AMR. #WholeGenomeSequencing #sepsis #healthtech #AMR #biotech #theAMRnarrative #genomekey